- Home
- FENC
as 12-17-2024 4:00pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 172.8M | IPO Year: | 2001 |
| Target Price: | $14.00 | AVG Volume (30 days): | 173.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.96 - $11.92 | Next Earning Date: | 11-07-2024 |
| Revenue: | $49,348,000 | Revenue Growth: | 278.09% |
| Revenue Growth (this year): | 97.94% | Revenue Growth (next year): | 11.50% |
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Raykov Rosty | FENC | Director | Dec 5 '24 | Sell | $6.04 | 796 | $4,807.84 | 66,432 | |
| RALLIS CHRIS A | FENC | Director | Dec 2 '24 | Sell | $6.14 | 6,409 | $39,351.26 | 52,214 | |
| Raykov Rosty | FENC | Director | Dec 1 '24 | Sell | $6.13 | 1,635 | $10,022.55 | 66,432 | |
| Raykov Rosty | FENC | Director | Oct 31 '24 | Sell | $4.31 | 2,431 | $10,477.61 | 66,432 | |
| RALLIS CHRIS A | FENC | Director | Oct 8 '24 | Sell | $4.53 | 1,406 | $6,369.18 | 52,214 | |
| Raykov Rosty | FENC | Director | Sep 30 '24 | Sell | $4.94 | 2,431 | $12,009.14 | 66,432 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
GlobeNewswire
a month ago
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
Simply Wall St.
a month ago
Fennec Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations
GuruFocus.com
a month ago
Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...
MT Newswires
a month ago
Fennec Pharmaceuticals Q3 Loss Widens as Expenses Rise
GlobeNewswire
a month ago
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
2 months ago
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Simply Wall St.
2 months ago
Individual investors account for 31% of Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) ownership, while hedge funds account for 30%
Compare FENC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.